Patients : Immune Disorders

Octapharma develops and manufactures high-purity human immunoglobulin products for treating immune-mediated diseases and deficiencies.

 

We are committed to setting new standards in immunotherapy product development in order to improve patient outcomes. We strive for tangible added value to patients, such as excellent intravenous immunoglobulin tolerability, even without premedication and at high infusion rates.

Immune-Mediated Diseases and Deficiencies

The immune system plays a key role in numerous conditions. In so-called immune deficiencies, the patient is prone to severe infections due to a lack of naturally occurring protective antibodies (immunoglobulins). Such patients need replacement of the missing immunoglobulins in order to protect them against infections and ensure they can lead a normal life.

 

Conditions where the immune system is out of balance are generally referred to as immune-mediated diseases, of which auto-immune diseases are a well-known subgroup. Such conditions may lead to various diseases, including bleeding disorders with a reduced number of blood platelets (immune thombocytopenic purpura (ITP)) and inflammatory neurologic conditions such as Guillain-Barré-Syndrome (GBS), chronic demyelinating polyradiculoneuropathy (CIDP) or multiple sclerosis (MS). Many other organ systems can also be a target of an immune-mediated disease.

 

Immunotherapy treats immune diseases and deficiencies by inducing, enhancing, or suppressing an immune response through immunomodulation or immunoglobulin replacement therapy.

 

Indications for Octapharma's immunotherapy products

    • Primary Immunodeficiency (PID)
    • Myeleoma and chronic lymphatic leukaemia (CLL) with severe secondary hypogrammaglobulinaemia
    • Immune thrombocytopenic purpura (ITP)
    • Kawasaki disease
    • Guillain Barre Syndrome (GBS)
    • Children with congenital AIDS and recurrent infections
    • Allogeneic bone marrow transplantation

 

Indications for Octapharma's immunotherapy products under clinical trial include:

  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

  • Alzheimer's disease